

NDA 202736/S-009

**SUPPLEMENT APPROVAL**

Arbor Pharmaceuticals LLC  
Attention: Justin Kilby  
Associate Director, Regulatory Affairs  
6 Concourse Parkway  
Suite 1800  
Atlanta, GA 30328

Dear Mr. Kilby:

Please refer to your supplemental new drug application (sNDA) dated and received on February 5, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Sklice (ivermectin) lotion, 0.5%.

This Prior Approval supplemental new drug application provides for an alternative manufacturing, packaging and testing facility, a change to the primary container, and changes to labeling.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**LABELING**

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling described in the table below and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

| <b>Submitted Labeling</b>                      | <b>Date of Submission</b> |
|--|---------------------------|
| Sklice Outer Carton                            | February 5, 2021          |
| Sklice Immediate Container (Front) – 4 oz Tube | April 22, 2021            |
| Sklice Immediate Container (Back) – 4 oz Tube  | April 22, 2021            |
| Sklice Consumer Information Leaflet            | February 5, 2021          |

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.<sup>1</sup> For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 202736/S-009.**” Approval of this submission by FDA is not required before the labeling is used.

We remind you to remove the “**New**” flag from labeling 6 months after initial marketing.

## **DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.<sup>2</sup> Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

<sup>1</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>2</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

If you have any questions, call Phong Pham, PharmD, MBA, Regulatory Project Manager, at (301) 837-7656.

Sincerely,

*{See appended electronic signature page}*

Francis E. Becker, MD, FACP  
Director  
Division of Nonprescription Drugs II  
Office of Nonprescription Drugs  
Center for Drug Evaluation and Research

ENCLOSURES:

- Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

FRANCIS E BECKER  
05/28/2021 09:27:04 AM